Study summary
Bexicaserin cut motor seizures by about 60% in severe childhood-onset epilepsies
59.8%median drop in motor seizures, vs 17.4% with placebo
What was tested
Bexicaserin, a pill that activates the 5-HT2C serotonin receptor, or placebo in teens and adults with developmental and epileptic encephalopathies (DEEs) such as Dravet and Lennox-Gastaut syndromes.
What they found
- Countable motor seizures fell a median 59.8% vs 17.4%.
- Sleepiness was the most common reason to stop (16.3% during titration).
What it means
Now in a phase 3 trial (DEEp SEA) whose main analysis was due October 2026.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.